Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

BACKGROUND: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticle albumin-bound paclitaxel (nab(®)-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma (NPC). METHODS: Patients were enrolled into 1 of 3 dose cohorts, each with 21-day tre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Huang, Yan, Liang, Wenhua, Yang, Yunpeng, Zhao, Liping, Zhao, Hongyun, Wu, Xuan, Zhao, Yuanyuan, Zhang, Yang, Zhang, Li
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944269/
https://ncbi.nlm.nih.gov/pubmed/27411683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2517-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items